Binita Bhattacharjee
Berkeley, California, United States
500 connections
View Binita’s full profile
Other similar profiles
-
Munkhbold (Mike) Damdinjav
Technology Consulting
Cypress, TXConnect -
Sam Littlefield
Portland, ORConnect -
Matthew Gilliland
Los Angeles Metropolitan AreaConnect -
Monica Bhatia
San Ramon, CAConnect -
Bryson Rupnik
Charlottesville, VAConnect -
Stephanie Loucas
San Francisco, CAConnect -
Sonya Vial
Houston, TXConnect -
Prasenjeet Ghosh
Greater HoustonConnect -
Peter A. Bruno
Troy, NYConnect -
Aaron Smith
Houston, TXConnect -
Alex Woravka
Spring, TXConnect -
Whitney Dobson
Chief Operating Officer
Austin, TXConnect -
Chandresh Thakker
Emeryville, CAConnect -
Stephen Fyfe
Houston, TXConnect -
Maryanne Kumiega
Vice President of Engineering at Birch Creek Energy
San Diego, CAConnect -
David Babson
Cambridge, MAConnect -
Rorik Peterson
Shawnee, KSConnect -
Andrew C. Hawkins, Ph.D.
St Paul, MNConnect -
Edison Liu
Boston, MAConnect -
Nazanin Rahimi
Houston, TXConnect
Explore more posts
-
Iuliana Barbalau Constantin
Thank you for those of you who attended my presentation at WUSS, Sacramento. #wuss2024 I am grateful for all of the great questions received, and also for those of you who shared your challenges getting into the Pharmaceutical/Biotech industry. Given that I was lucky and busy in the last 16 years working in the industry, I overlooked or forgot that getting my 1st job in the industry was through a ‘luck of draw’. I am fortunate that I worked in a field that provided professional rewards for so many years, that I created from my work colleagues long term friendships. Now, my focus is on setting training modules to help future generations get the ‘hands-on’ work experience to join the Pharmaceutical/Biotech industry (www.coepharma.com). Through the discussions held with different individuals, I was taken by surprise of existing ‘mismatches’ (for example a medical degree holder working as a SDTM program, when that person would definitely be a better fit for Safety/Pharmacovigilance group) in the Biotech industry. And with this I am reaching another issue…many students or college graduates choose one school, or another based on their perception of what the real work would look like or based on the ‘school brand’ name or salary/benefits options. Very few of the students and young professionals have a good mentor to sit down with them and explain what options they have, and what they would be doing at their ‘dream’ job. Given that we spend a lot of time at work, having a good fit between what we want and can actually accomplish and what the job requirements are is priceless. I would love to get your feedback. Do you remember how you got your 1st job? Do you have suggestion for a future colleague? If you are a student, why do you attend the school (what is your ultimate goal)? If you are a professional, what are the differences between the Academia and the real work?
141 Comment -
Aspen Alert
Layoffs Announced at 2 Big Bay Area Biotech Firms Two large Bay Area biotech firms have announced layoffs that will impact over 500 workers. Genentech will be cutting 436 jobs at its South San Francisco headquarters. Sanofi, which is headquartered in Paris, will also be cutting 100 jobs at its South SF office, according to notices filed with the California Employee Development Department. The Genentech layoffs were for employees at its HQ at 1 DNA Way in South San Francisco. The Sanofi layoffs are due to the planned closure of its South San Francisco facility at 2 Tower Place, according to EDD filings. Sanofi’s layoffs are scheduled to begin taking effect on June 3. According to the San Francisco Business Times, the job cuts are part of the company’s plan to divest itself from Amunix Pharmaceuticals Inc., a Peninsula drug maker it acquired in 2021. https://lnkd.in/gvtQdvdP #aspenalert #biotech #bioprocess
1 -
Ron Cohen, M.D.
I've been impressed by how John F. Crowley, new CEO of the Biotechnology Innovation Organization, has hit the ground running in his first 90 days, even as he had to address a crisis within his first 3 days(!) when BIO received a letter from Congress related to the BIosecure Act. As the outstanding biotech CEO he is, John has already updated BIO's key priorities and goals, reorganized and refocused the organization to concentrate force on achieving those goals, and repositioned BIO to give it an even more effective voice at the table regarding US policy related to #biotech #innovation and #security. His initiatives have been fully supported by BIO's Executive Committee and Board. John is positioning BIO to reflect the fact that #biotechnology is one of the US' most important strategic assets, and that the country must treat it as such. In this era of astonishing advances in our ability to intervene at the level of the genome, we must recognize that—as with the splitting of the atom—there is potential for enormous good, but also for almost unimaginable evil. A strong BIO will play key roles in helping us to navigate both the opportunities and threats.
24 -
Dr. Andreas Worberg
FERMENTATION’S GRAVEYARD - The synthetic biology company graveyard is crowded. ⚰ I would argue, a few undead are also still around 🧟♀️ (and some might argue that is me - just hard to kill) - #Synthetic #biology firms promised a #lowcarbon industry, but so far they haven’t delivered 😌 - great new piece of work from Matt Blois at C&EN - ➡Following a very good article on "Biomanufacturers will pursue small projects to weather the economic storm" by Matt at C&EN earlier this year https://lnkd.in/d7idUkp5 he has followed up with many "veterans" and "old guard" of the sector, but also bringing in fresh and new voices forward. Are we ever going to deliver and stand the storms of #hype #hypocrisy #technicalarrogance and #realitychecks ? ➡ Quote: “It was total belief. Total excitement. Total focus. . . . The problem was that it was predicated on a false promise.” Love it. Been there. yes. ➡ Start small: "For firms that survived the biofuel era, and start-ups that have emerged since then, the demise of Amyris and its competitors offers a lesson: start small or die." ➡ You've got to pay for that carbon The International Monetary Fund estimates that the fossil fuel industry is effectively supported by $7 trillion in subsidies per year, which come largely in the form of government spending to deal with petroleum’s negative impacts. Now - discussion is on. Share your thoughts and "war stories" - I am fortunate I was able to contribute to this article with some of my own insights during the "drop-in" chemicals and fuels days and spending a previous life in this part of the industry. Thanks Matt.
251 Comment -
Naresh Waran Gnanasegaran
Labour Day, also known as International Workers' Day or May Day, is celebrated on May 1st each year. ✨ Historical Origins: - The roots of Labour Day trace back to the Haymarket Affair in 1886. In Chicago, American laborers were advocating for an 8-hour workday, which they believed was fair. However, peaceful protests escalated into violence, resulting in deaths and injuries. - Despite the turmoil, socialist parties across Europe convened in 1889 and designated May 1 as International Labour Day. This day symbolizes hope and resilience for workers worldwide, even in challenging circumstances. ✨ Significance: ✅ Honoring Workers: Labour Day recognizes the vital role played by workers and the working class in shaping our societies. It reminds us that their commitment and loyalty cannot be quantified by mere monetary compensation. ✅ Advocacy for Rights: Beyond a public holiday, Labour Day serves as a platform to acknowledge the contributions of individuals to societal development without bias. It emphasizes the importance of workers' rights and welfare. ✅ Global Celebration: Countries around the world join hands on May 1 to celebrate the hard work and dedication of workers, regardless of their roles. It's a day to express gratitude and appreciation for their tireless efforts. Happy Labour Day dear friends 💐
2 -
Niko Christopher Bockmon
NSF announces pilot for startups and small businesses to 'fast-track' successful development of technological innovations The NSF Small Business Innovation Research/Small Business Technology Transfer Fast-Track pilot provides eligible teams the opportunity to submit one proposal for more than $2 million over up to three years Today, the U.S. National Science Foundation launched a pilot initiative for startups and small businesses to develop new products and services based on prior NSF-funded research. Eligible companies can submit one proposal for more than $2 million for a "Fast-Track" award to support research and development activities that may take up to three years to complete. "NSF invests in startups and small businesses that bring the most innovative, cutting-edge technologies to the market and society," said Barry Johnson, division director of Translational Impacts in the NSF Directorate for Technology, Innovation and Partnerships (TIP). "These companies have the potential to become great commercial successes and contribute significantly to economic growth and job creation throughout the nation. With this pilot, we are excited to provide a more rapid and seamless pathway for startups and small businesses to obtain the research and development funding that they need to accelerate product development." Unlike NSF's traditional Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs that require multiple proposal submissions to receive an equivalent amount of investment, the NSF SBIR/STTR Fast-Track award provides an immediate pathway to a full funding commitment of more than $2 million over three years. Typically, NSF SBIR/STTR funding is a two-step process: a startup or small business first applies for and receives a Phase I award and, after successful completion of the Phase I award, is eligible to apply for a Phase II award to continue its research and development activities. In contrast, the SBIR/STTR Fast-Track pilot operates by requiring periodic reviews that can trigger more than $2 million per project, reducing administrative burden for both small businesses and NSF, and focusing on what matters most: getting innovations from the lab to the market and society. Also known as America's Seed Fund powered by NSF, SBIR/STTR programs are congressionally mandated research and development funding programs intended to support startups and small businesses focused on bringing innovative technologies to the market and society. The deep technologies in which NSF invests show promise, but their success requires further validation, derisking and feasibility assessment. Each year, the agency invests about $250 million in research and development funding, benefiting about 400 startups and small businesses across the United States. A portion of these funds will be used for this pilot initiative. .
-
Partnology
Versant Ventures debuts Santa Ana Bio, Inc. (Alameda) with $168 million and a trio of programs that riff in new ways on existing ideas like targeting mast cells and stimulating the PD-1 pathway. One of Santa Ana’s drugs, dubbed SAB01, is a so-called bispecific #antibody. It is designed to mute the mast cells that drive allergic disease by blocking a protein called c-Kit. But the drug will only do so when it detects another target that’s found on those cells. Foresite Capital (Larkspur) an investment firm that backs life sciences and healthcare companies, has raised a $900 million fund. The fund, Foresite’s sixth, will invest in companies focused on precision medicine, healthcare delivery and life sciences infrastructure. In drug developers, specifically, the firm is looking for those using #genetics and #machinelearning to identify potential therapies. Actio Biosciences, Inc. (San Diego) announces $55 Million Series A financing to deploy a suite of proprietary tools and deep #genetics expertise to develop #therapeutics against targets shared between rare and more prevalent diseases. They have a lead small molecule program targeting TRPV4 mutations advancing toward clinic for treatment of Charcot-Marie-Tooth disease type 2C and other serious bone diseases. Actio also announced an innovative partnership with The Jackson Laboratory to develop and implement new transgenic models of rare disease pathways. M&A, Deals, Partnerships: Johnson & Johnson is handing back a bispecific T cell engager program designed to target both CD20 and CD3 to its partner Xencor, ending a significant piece of an agreement between the companies that started in 2021. Xencor completed enrollment for a Phase 1 trial of plamotamab last year. The biotech said the drug is now Phase 2-ready, adding it will review its potential to address unmet needs. The original collaboration and license deal saw Xencor get $100 million upfront for global development and commercialization rights to plamotamab. Other Interesting News: The failure of a Pfizer medicine for #Duchenne muscular dystrophy adds new uncertainty around the effectiveness of #genetherapy for the muscle-wasting condition. Pfizer said the treatment missed its mark in a definitive Phase 3 study of boys between 4 and 7 years of age with DMD. Pfizer said the therapy didn’t lead to a significant difference versus placebo on a measure of motor function, or on key secondary measures such as timed tests for how quickly study participants could stand or walk. Avidity Biosciences, Inc. (San Diego) drug for muscular dystrophy shows promise. Shares in Avidity rose by nearly one-third as the company revealed new clinical trial data for its drug del-brax in a form of #musculardystrophy. Among eight patients treated with del-brax, Avidity reported greater than 50% average reduction in a panel of genes regulated by another gene called DUX4. Avidity also said participants showed signs of increased strength.
12 -
Nick Hutchinson
Roche's recent decision to offload their Vacaville facility highlights the increasing importance of cell line productivity in biomanufacturing strategy. According to Dan Stanton of Bioprocess Insider, Roche is moving towards more high titer processes and products with lower volume demands. (You can read the article here https://lnkd.in/erRx597k) Agile manufacturing strategies are enabled by cell line productivity, which allows for the same amount of drug substance to be produced in smaller bioreactors. This, in turn, allows for smaller clean rooms and lower running costs. Just - Evotec Biologics' J.CHO High Expression System cell lines, grown in perfusion bioreactors, produce over 4 g/L of antibody each day, equivalent to around 30 g/L in fed-batch mode (https://lnkd.in/eexeJrQA). This level of productivity allows for commercial quantities of antibody to be manufactured in 1000L single-use bioreactors in our modular J.POD facilities. As a result, large-scale stainless-steel facilities are becoming redundant. The future of biomanufacturing lies in maximizing cell line productivity, and our J.CHO system is leading the way. #biomanufacturing #celllineproductivity #JCHO #JPod #agilemanufacturing 👨⚕️Philip Boehme
36 -
Scott Caputo
I worked in a CRISPR lab during my bachelors and this is insane: Profluent, a Berkeley startup, has created AI that generates novel CRISPR gene editors. The AI learns from analyzing vast biological data to create editors that have never existed in nature. And for context prior to this, CRISPR methods used mechanisms found in nature to explore new variations. This breakthrough points to a future of battling disease with greater precision and speed. And even crazier, Profluent literally open-sourced one of these AI-generated editors, OpenCRISPR-1, for free experimentation. While still very early, this technology holds immense potential. And in my personal opinion, could be the potential gateway for personalized medicine. AI is accelerating progress in healthcare and pushing boundaries faster than ever before. And at this point it's inevitable whether you like it or not.. From creating new proteins for vaccines to revolutionizing gene editing, the possibilities are endless. I definitely think we're witnessing a new era of medicine unfold. Does this excite you or worry you we're gonna see something out of the X-men? Follow Scott Caputo - every week I explore AI, innovation & strategy #AI #GeneEditing #Healthcare #Biotech #Innovation
123 Comments -
William Canestaro, PhD
Congratulations to Alex, Lindsay, Michelle, and the rest of the Talus Bio team on the latest financing! This will be transformative for the team as they work to develop new drugs to target transcription factors. 👩🔬 What does the company do? Talus uses their platform to test for the effect of novel TF-targeted drugs in a live cell opening up the possibility of drugging many previously 'undruggable' targets. 💊 What do they have so far? The company is working on four targets including #brachyury for treating a rare cancer called #chordoma. 💸 Who is investing? The round is led by a stellar team at Two Bear Capital (J. Seth Strattan PhD and Avery Sonnenberg), with participation from Washington Research Foundation, BoxOne Ventures, and NFX 🌎 Why does this matter? Talus has an impressive technology that hopefully can create new treatment options for some serious conditions. The team worked doggedly to build the company off of grants in a harsh market cycle and this investment validates how far they've come. I'm excited to have this team in Seattle helping build the next generation of great biotech companies here! #biotech #financing #company #seattle
781 Comment
Explore collaborative articles
We’re unlocking community knowledge in a new way. Experts add insights directly into each article, started with the help of AI.
Explore MoreOthers named Binita Bhattacharjee
-
Binita Bhattacharjee
Channel Team Lead
Guwahati -
Binita Bhattacharjee
Company Secretary - Institute of Company Secretaries of India, ICSI, Eastern India Regional Council MBA in Finance & Banking
Thane -
Binita Bhattacharjee
HR Executive at Tax Connect Advisory Services LLP
Kolkata -
Binita Bhattacharjee
Hunt with the big dogs or be relegated to the porch
Hajo
11 others named Binita Bhattacharjee are on LinkedIn
See others named Binita Bhattacharjee